Many companies are looking to build on the blockbuster success...

Many companies are looking to build on the blockbuster success of PD1 inhibitors like Bristol Myers Squibb‘s Opdivo and Merck‘s Keytruda (these are the two companies imugene is chasing via the development of PD1-Vaxx)

......Chasing the same indications as a world-beater like Merck & Co.'s Keytruda is no easy task, but Bristol Myers Squibb's sales superstar Opdivo has held its own in the lucrative immuno-oncology field. ... Opdivo hit $8.06 billion in 2019 and could be set for 5% growth each year through 2026, Evaluate Pharma predicts.27 July 2020...

.....Keytruda could add $3.29 billion in worldwide sales to its 2019 haul of $11.1 billion, according to Evaluate Pharma, bringing its total for 2020 to $14.39 billion.14 Apr 2020....

These values are what PD1 could possibly earn Imugene via a T/O scenario. Real numbers that can impact a stock significantly.

Another point is the following .... For the third and final stage of the study, at least three cancer patients will receive 100 micrograms of PD1-Vaxx, double the dose of the previous cohort....

Current drugs administer the following....How much does Keytruda cost? Keytruda is a brand-name prescription drug so it has a high out-of-pocket cost without insurance. According to the manufacturer, a single 200-mg intravenous dose of Keytruda costs $9,724.08 without insurance.27 Aug 2020...

..while -> OPDIVO as monotherapy The recommended dose of OPDIVO is either nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks ....

Imugene's 3rd dose and final stage, if successful in limiting toxicity and side affects, will only still be half the quantity of proven drugs administered. If so big pharma could/should/will/may (YOU CHOOSE WHICH) show some interest!!!

NB: Paul Hopper recently listed another stock Chimeric Therapeutics Ltd0.30 AUD, he may need fast cash so again I think a T/O is the delivery of choice of $$ for shareholders.